Von Willebrand's disease: A report from a meeting in the Åland islands

Haemophilia

Volumn 18, Issue SUPPL.6, 2012, Pages 1-13

  Berntorp, E ^a   Peake, I ^b   Budde, U ^c   Laffan, M ^d   Montgomery, R ^e   Windyga, J ^f   Goodeve, A ^g   Petrini, P ^h   von Depka, M ⁱ   Miesbach, W ^j   Lillicrap, D ^k   Federici, A B ^l   Lassila, R ^m   White, G ⁿ  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e Children's Hospital of Wisconsin   (United States)

^f INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Werlhof Institut   (Germany)

^j Hämophiliezentrum Frankfurt ^*  (Germany)

^k QUEEN S UNIVERSITY   (Canada)

^l UNIVERSITY OF MILAN   (Italy)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ BLOOD RESEARCH INSTITUTE   (United States)

more..

Author keywords

Factor VIII; Prophylaxis; Treatment; Von Willebrand factor; Von Willebrand's disease

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; RISTOCETIN; VON WILLEBRAND FACTOR;

AUTOSOMAL INHERITANCE; BIOCHEMISTRY; BLEEDING; BLEEDING TIME; BLOOD TRANSFUSION; CELL ADHESION; CELL WALL; DISEASE CLASSIFICATION; DNA DETERMINATION; EPISTAXIS; EXTRACELLULAR MATRIX; GASTROINTESTINAL HEMORRHAGE; GENETICS; GLYCOSYLATION; HEMARTHROSIS; HUMAN; ORAL BLEEDING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SURGICAL TECHNIQUE; THROMBOCYTE ADHESION; THROMBOCYTE ADHESIVENESS; VON WILLEBRAND DISEASE;

FACTOR VIII; GENETIC THERAPY; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; SCANDINAVIA; UNITED STATES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84865387027     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02925.x     Document Type: Review

References (49)

1. Von Willebrand EA. Hereditär pseudohemofili. Finska Läkarsällskapets Handl 1926; 67: 7-112.
2. Nilsson IM. The history of von Willebrand disease. Haemophilia 1999; 5(Suppl. 2): 7-11.
3. Von Willebrand EA. Über hereditäre Pseudohämaphilie. Acta Med Scand 1931; 67: 521-50.
4. Von Willebrand EA. Über ein vererbbares Blutungsübel: Die konstitutionelle Thrombopathie. Dtsch Arch Klin Med 1933; 175: 453-83.
5. Soulier JP, Larrieu MJ. Willebrand-Jürgens syndrome and thrombopathies, study of 66 cases; attempt at classification. Rev Hematol 1954; 9: 77-122.
6. Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotype and molecular data. Hematology Am Soc Hematol Educ Program 2009; January 1: 113-23.
7. Ruggeri ZM, Zimmerman TS. Classification of variant von Willebrand's disease subtypes by analysis of functional characteristics and multimeric composition of factor VIII/von Willebrand factor. Ann N Y Acad Sci 1981; 370: 205-9.
8. Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood 1987; 70: 895-904.
9. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-5.
10. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
11. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992; 267: 8723-31.
12. Titani K, Kumar S, Takio K et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-84.
13. Williams DB. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 2006; 119: 615-23.
14. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.
15. McGrath RT, McKinnon TA, Byrne B et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood 2010; 115: 2666-73.
16. Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT. The RIIIS/J inbred mouse strain as a model for von Willebrand disease. Blood 1990; 76: 2258-65.
17. Flood VH, Gill JC, Morateck PA. et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116: 280-6.
18. Pasi KJ, Collins PW, Keeling DM. et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 218-31.
19. Mannucci PM, Franchini M, Castaman G, Federici AB; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
20. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-34.
21. Hyatt SA, Wang W, Kerlin BA, O'Brien SH. Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population. Pediatr Blood Cancer 2009; 52: 102-7.
22. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14(Suppl. 5): 47-53.
23. Witmer CM, Elden L, Butler RB, Manno CS, Raffini LJ. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures. J Pediatr 2009; 155: 68-72.
24. Stray-Pedersen A, Omland S, Nedregaard B, Klevberg S, Rognum TO. An infant with subdural haematoma and retinal haemorrhages: does von Willebrand disease explain the findings? Forensic Sci Med Pathol 2011; 7: 37-41.
25. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S23-6.
26. Dunkley S, Baker RI, Pidcock M. et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study. Haemphilia 2010; 16: 615-24.
27. Berntorp E, Windyga J; European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-30.
28. Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus 2008; 6(Suppl. 2): S26-32.
29. Borel-Derlon A, Federici AB, Roussel-Robert V. et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-24.
30. Berntorp E. Personal communication.
31. Klenk J, Rapp K, Büchele G, Keil U, Weiland SK. Increasing life expectancy in Germany: quantitative contributions from changes in age- and disease-specific mortality. Eur J Public Health 2007; 17: 587-92.
32. Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985; 59: 593-602.
33. Franchini M, Lippi G, Favaloro EJ. Advances in hematology. Etiology and diagnosis of acquired von Willebrand syndrome. Clin Adv Hematol Oncol 2010; 8: 20-4.
34. Tosetto A, Rodgehiero F, Castaman G. et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
35. Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost 2007; 5(Suppl. 1): 157-66.
36. Zhang Z, Eriksson M, Blombäck M, Anvret M. A new approach to gene therapy. Blood Coagul Fibrinolysis 1997; 8(Suppl. 2): S39-42.
37. Federici AB, Barillari G, Zanon E. et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia 2010; 16: 101-10.
38. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
39. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
40. Sarji KE, Stratton RD, Wagner RH, Brinkhous KM. Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc Natl Acad Sci USA 1974; 71: 2937-41.
41. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
42. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-55.
43. Laffan M, Brown SA, Collins PW. et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217.
44. Dean JA, Blanchette VS, Carcao MD. et al. von Willebrand disease in a pediatric-based population - comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Wiillebrand factor/collagen binding assay. Thromb Haemost 2000; 84: 401-9.
45. Berntorp E, Önundarson PT. Prevalence of von Willebrand disease in the Nordic region. Haematologica Rep 2005; 1: 4-6.
46. Lassila R, Holme PA, Landorph A, Petrini P, Önundarson PT, Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. Semin Thromb Haemost 2011; 37: 495-502.
47. Lethagen S, Ingerslev J, Holme PA, Petrini P, Lassila R, Önundarson PT. Nordic Guidelines for Diagnosis and Management of von Willebrand Disease. Guidelines of the Nordic Hemophilia Council. Available at: http://nordhaemophilia.org/document/NordicGuidelinesVWD_SL23APR2008b.pdf.Accessed July 26, 2012.
48. Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
49. Berntorp E, Ingerslev J, Schulman S. von Willebrand disease: an update in the Åland islands. Summary of a Nordic symposium on von Willebrand disease, 24-25 September 1998, Mariehamn, Åland. Haemophilia 1999; 6(Suppl. 2): 1-6.